摘要
目的探讨TP方案和NP方案诱导化疗局部晚期NSCLC的疗效优势。方法收集我院2008年1月至2010年1月接受化疗的晚期非小细胞肺癌患者(其中鳞癌26例,腺癌44例,大细胞肺癌32例)102例,随机分为TP方案化疗组(A组,51例)和NP方案化疗组(B组,51例)。比较两组不同化疗方案治疗局部晚期NSCLC的近期疗效、Karnofsky评分、毒副反应和随访1、2年的生存情况。结果 A、B两组的总有效率分别为54.9%和43.1%,生活质量改善率分别为80.4%和72.5%,1年生存率分别49.0%和45.1%,2年生存率分别13.7%和11.8%,中位生存期为14.5和13个月,A组略优于B组,但两组疗效在统计学上均无显著性差异(P<0.05)。两组在毒副反应方面静脉炎、脱发等副反应方面有统计学差异(P<0.05)。结论 TP方案和NP方案诱导化疗局部晚期NSCLC均为合理,安全,有效的两种方案,均可作为一线方案推荐临床应用,但TP方案比NP方案在患者耐受性和不良反应方面更好。
Objective To evaluate the efficacy of induction chemotherapy for patients with local advanced non-small cell lung cancer（NSCLC） between TP and NP regimen. Methods collecting 102 advanced non-small-cell lung cancer patients （ Including 26 ca- ses of squamous cell carcinoma, 44 cases of adenocarcinoma and 32 cases of large cell lung cancer）who have received Chemotherapy dur- ing February, 2008 to February, 2010 in our hospital as our study subjects. The patients were randomly divided into two groups, group one （ group A, n = 51 ） was treated with TP chemotherapy and group two （ group B, n = 51 ） was treated with NP chemotherapy. We trying to compare the curative effect, Karuofsky scores,the toxic and adverse effects and the survival condition after one and 2 years between these pairs. Results The total effective rate of the group A and group B was 54.9% and 43. 1%, and the rate of quality of life improvement was 80. 4% and 72.5%. The accumulate survival rate after one year of the group A and group B was 49.0% and 45.1%, accumulate survival rate after two year was 13.7% and 11.8%. Two groups of curative effect had no significant difference in statistically. Complica- tions of two groups, hair loss and phlebitis with significant differences （ P 〈 0. 05 ）. Conclusion Both the chemotherapy TP and NP methods are reasonable, safe, effective treatments for locally adanced NSCLC, could be used as first-line schemes for the clinical application, but tolerance and adverse reaction of TP method is better than NP method.
出处
《临床肺科杂志》
2013年第2期222-224,共3页
Journal of Clinical Pulmonary Medicine
